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How SLPI soothes
 
Organs such as the lung that are continuously exposed to inhaled microbes 
must be carefully guarded against excessive inflammation. A new study by 
Taggart and colleagues on page 1659
 
 
 
shows that a protease inhibitor that 
is produced in the airways helps subdue lung inflammation by shutting 
down the pro-inflammatory transcription factor NF-
 
 
 
B, both in the 
cytoplasm and the nucleus.
One way the lung avoids inflammation-induced collateral damage is by 
producing protease inhibitors, such as SLPI (secretory leukocyte protease 
inhibitor). SLPI is produced by mucosal epithelial cells and inactivates 
potentially damaging enzymes, such as neutrophil elastase, that are produced 
by immune cells to help kill invading microbes.
But SLPI’s protective function is not limited to defusing dangerous 
proteases. SLPI is also a potent antimicrobial peptide (akin to defensins) and 
an antiinflammatory agent. This group and others have shown that SLPI’s 
antiinflammatory activity stems in part from its ability to inhibit the 
degradation of I
 
 
 
B
 
 
 
—an inhibitor protein that binds to cytoplasmic NF-
 
 
 
B. 
The importance of SLPI in limiting inflammation is evident in SLPI-deficient 
mice, which succumb to endotoxic shock in response to normally sublethal 
doses of bacterial lipopolysaccharide.
Here, Taggart and colleagues show that SLPI also targets NF-
 
 
 
B in the 
nucleus, where SLPI binds to 
 
 
 
B binding sites on gene promoters, displacing the 
SLPI (green) enters the nucleus (red) of monocytes and 
competes with NF- B for binding to gene promoters.
 
NF-
 
 
 
B protein p65. This competition inhibits the production of inflammatory 
cytokines such as interleukin (IL)-8 and TNF. Thus, any NF-
 
 
 
B protein that 
circumvents SLPI’s roadblock in the cytoplasm would likely encounter a second 
wave of SLPI-mediated resistance in the nucleus.
The preferential production of this multifunctional protein at mucosal 
 
Chemokine drives tuberculosis
 
High levels of the chemokine monocyte
chemoattractant protein-1 (MCP-1)
give tuberculosis (TB) the upper hand,
according to a population study on page
1649. Flores-Villanueva and colleagues
show that individuals whose cells are gen-
etically programmed to produce copious
amounts of MCP-1 are more likely to
develop active disease when infected
with 
 
Mycobacterium tuberculosis.
Tuberculosis patients homozygous for the 
MCP-1 –2518G allele (GG) have the highest 
plasma levels of MCP-1.
 
Infections with 
 
M. tuberculosis
 
, the
causative agent of TB, are on the rise; an
estimated eight million new infections
and two million TB-induced deaths
occur annually. But not all people who
are exposed to 
 
M. tuberculosis
 
 become ill—
a phenomenon largely attributed to genetic
differences that make some individuals
more susceptible to disease than others.
Indeed, a recent study identified a region
on chromosome 17 that was linked to
increased susceptibility to active tubercu-
losis, although the exact gene(s) responsible
for this effect was not identified.
Flores-Villanueva and colleagues
now show that a polymorphism in the
promoter of the 
 
MCP-1
 
 gene, which
resides on chromosome 17, is the likely
culprit of this increased susceptibility. In
a group of infected individuals from
Mexico, this polymorphism (-2518G)
was five times more prevalent in patients
with active TB than in those who re-
mained healthy. This polymorphism was
previously shown to cause increased
expression of the MCP-1 protein.
MCP-1 is an attractant for monocytes
and T cells, two cell types that help to
form the granulomas that contain the
bacteria, and is thus thought to help or-
chestrate the initial response to 
 
M. tubercu-
losis
 
 infection. But extremely high levels
of MCP-1 can inhibit the expression of
interleukin (IL)-12, a cytokine primarily
produced by dendritic cells and mono-
cytes that is required to activate antibac-
terial effector cells. Indeed, monocytes
isolated from patients homozygous for the
-2518G allele produced high levels of
MCP-1 and low levels of IL-12 when
stimulated with 
 
M. tuberculosis
 
 extracts.
In an accompanying commentary
(page 1617), Alcais and colleagues note that
the presence of the -2518G susceptibility
allele in approximately half of the Mexican
population means that, in the absence of
other genetic factors, the attributable risk
of this mutation for developing disease
could exceed 60%—the largest genetic
impact on adult TB ever described. 
 
surfaces probably reflects the importance of preventing 
excessive immune activation in tissues barraged by 
environmental pathogens. Whether SLPI-mediated 
inhibition is defective in individuals prone to chronic 
inflammatory diseases of the mucosa, such as asthma or 
inflammatory bowel disease, remains to be tested. 
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